THE USE OF GASTROENTEROLOGICAL DRUGS ON THE OUTCOME OF TREATMENT IN COVID-19

Abstract

The study included 1124 patients with COVID-19. Of these, 510 were discharged and 614 died. The patients were divided into 2 groups: the main of 617 cases treated with gastroenterological agents; control of 507 patients who did not receive these funds.Within the groups, 2 subgroups were distinguished according to the outcome of treatment: those who died and those who were discharged. The proportion of patients who died from COVID-19 received gastroenterological agents in 69.4% of cases, and among those who survived — in 37.5% of cases. At the same time, 52.1% of patients with COVID-19 received 2 or more gastroenterological drugs.In the group of patients with COVID-19 who received gastroenterological agents, the incidence of respiratory failure was insignificantly higher (61.3%) than in the control group without these agents (39.5%). The presence of ARDS, regardless of therapy, often resulted in a poor outcome. The main complaints of hospitalized patients with COVID-19 were fever (74.9%), general weakness (70.5%), cough (64.9%), shortness of breath (61.1%). Cough, shortness of breath, fever were significantly more common among discharged patients compared with those who died. Thus, the use of gastroenterological drugs can contribute to the development of a lethal outcome.